



AD-A235 709 		TATION PAGE		Form Approved OMB No. 0704-0188
		<small>To average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering the collection of information, Send comments regarding this burden estimate or any other aspect of this form to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson at Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.</small>		DATE 0
1. AUTHOR(S) Fitz et al.		5 FUNDING NUMBERS Program Element No. NWED QAXM		6 AUTHOR(S) Fitz et al.
7 PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Armed Forces Radiobiology Research Institute Defense Nuclear Agency Bethesda, MD 20889-5145		8 PERFORMING ORGANIZATION REPORT NUMBER SR91-4		9 SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) Defense Nuclear Agency Washington, DC 20305
10 SPONSORING/MONITORING AGENCY REPORT NUMBER		11 SUPPLEMENTARY NOTES		
12a DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release; distribution unlimited.		12b DISTRIBUTION CODE		
13 ABSTRACT (Maximum 200 words)		14 SUBJECT TERMS		
15 NUMBER OF PAGES 13		16 PRICE CODE		
17 SECURITY CLASSIFICATION OF REPORT UNCLASSIFIED		18 SECURITY CLASSIFICATION OF THIS PAGE UNCLASSIFIED		19 SECURITY CLASSIFICATION OF ABSTRACT UNCLASSIFIED
20 LIMITATION OF ABSTRACT		21 LIMITATION OF ABSTRACT		

DTIC
SELECTED
MAY 09 1991



Acquisition For
 NTIS GRA&I
 DTIC TAB
 Unannounced
 Justification
 By
 Distribution/
 Availability Codes
 Avail. and/or
 Dist. prices
A1 20

Unte file 001



PROSTAGLANDINS

INTERACTION OF LEUKOTRIENE C₄ AND CHINESE HAMSTER LUNG FIBROBLASTS (V79A03 CELLS). 1. CHARACTERIZATION OF BINDING
T.A. Fitz^{1,4}, D.F. Contois¹, Y.X. Liu¹, D.S. Watt², T.L. Walden, Jr.³

¹Department of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20889-4799, ²Department of Chemistry and Division of Medicinal Chemistry, Lucille Parker Markey Cancer Research Center, University of Kentucky, Lexington, Kentucky 40506-0055, ³Radiation Biochemistry Department, Armed Forces Radiobiology Research Institute, Bethesda, Maryland 20889-5145, ⁴Correspondence

Abstract

A novel, specific, and potent biological action of leukotriene C₄ (LTC₄) was demonstrated in the Chinese hamster lung fibroblast cell line V79A03 (V79 cells), namely the conferment of protection against subsequent γ -irradiation. Consequently, studies were conducted to determine whether LTC₄-conferred radioprotection could be attributed to a receptor-mediated phenomenon. Specific binding sites for leukotriene C₄ (LTC₄) were identified and characterized using intact V79 cells incubated at 4°C in the presence of serine-borate, during which time conversion of LTC₄ to LTD₄ or LTE₄ was undetectable. Binding was maximal in a broad region between pH 6.2 and 8.8. Ca²⁺, Mg²⁺, and Na⁺ were not required for binding, and binding was not altered by GTP, ATP, or cAMP, by leukotrienes B₄, D₄, or E₄, or by the leukotriene end point antagonists LY 171883, FPL 55712, or Revlon 5901-5. Scatchard analyses and kinetic experiments indicated the presence of high-affinity [K_d = 2.5 ± 0.63 nM, approximately 9.9 × 10⁵ sites/cell] and low-affinity [K_d = 350 ± 211 nM, approximately 2.7 × 10⁶ sites/cell] binding sites. The observed binding characteristics of LTC₄ to V79 cells are consistent with a receptor-mediated phenomenon. In a companion communication which follows this report, we report the subcellular distribution of LTC₄ binding to V79 cells and demonstrate that this binding is unlikely to be attributed principally to interaction with glutathione-S-transferase.

Introduction

Eicosanoids have come under increasing scrutiny as possible agents to alleviate the damaging effects of ionizing radiation and because elevated eicosanoid synthesis by certain tumors is associated with their resistance to chemotherapy and radiation therapy (1). An *in vitro* model system was recently described (2) to evaluate the radioprotective effects of eicosanoids in the Chinese hamster lung fibroblast cell line V79A03 (V79 cells). In this system, pretreatment of V79 cells with leukotriene C₄ (LTC₄) elevated the cellular rate of postirradiation survival. The radioprotective effects of LTC₄ on V79 cells were attenuated if the cells to be treated were harvested from culture flasks by trypsin preincubation (unpublished data), suggesting that the radioprotective effect of LTC₄ depends on the presence of a proteinaceous factor present on the V79 cell surface.

In addition to its effect in V79 cells, pretreatment with LTC₄ was radioprotective in murine hematopoietic stem cells *in vivo* (3) and

PROSTAGLANDINS

enhanced animal survival following otherwise lethal radiation exposure (4). The mechanism(s) by which LTC₄ induced this protection has not been elucidated. The magnitude of the protection *in vivo* (3) was greater than the protection observed *in vitro* (4), indicating that specific cellular activities as well as physiological processes at the tissue and organ level may be important *in vivo*. The V79 cell provides a controlled model system in which to specifically study the cellular responses to LTC₄ that are important in the radioprotective response. In view of the observation that trypsinization attenuated LTC₄-induced radioprotection in the V79 model, studies were conducted to assess the possibility that LTC₄ receptors could be detected on V79 cells. The properties of LTC₄ interaction with V79 cells are described in this communication. In the companion communication that follows this report (5), we describe additional studies that determine the subcellular localization of LTC₄ binding by V79 cells and demonstrate that this binding site is distinct from that of glutathione S transferase, which is known to bind LTC₄.

Methods

Materials. Leukotrienes were a gift from Dr. J. Rokach (Merck Frosst Canada, Inc., Pointe Claire-Dorval, Quebec). Prostaglandin D₂ was a gift from Dr. D. Morton (Upjohn, Kalamazoo, MI). Other unlabeled eicosanoids were obtained from Cayman Chemical (Ann Arbor, MI). Tritiated eicosanoids and Aquasol-2 were obtained from New England Nuclear (Boston, MA). The leukotriene end point antagonists FPL 55712, LY 171883, and Revlon 5901-5 were gifts from Dr. A. Taub (Fison Corp., Bedford, MA), Mr. W. Fields (Lilly Research Laboratories, Indianapolis, IN), and Dr. T. P. Pruss (Rorer Group, Inc., Tuckahoe, NY), respectively. Nucleotides, trypsin, neuraminidase, hyaluronidase, glutathione-S-transferase, and 1-chloro-2,4-dinitrobenzene were obtained from Sigma (St. Louis, MO); Whatman glass-fiber filters (GF/B) from Fisher Scientific (Pittsburgh, PA); Iscove's Modified Dulbecco's Medium (IMDM), Medium 199 (M199), Hank's buffered salt solution (HBSS) and Ca²⁺, Mg²⁺-free HBSS from MA Bioproducts (Walkersville, MD); α -minimal essential medium (MEM) with Earle's salts and fetal bovine serum (FBS) from Gibco (Grand Island, NY); and KINETIC-LIGAND program from Elsevier-Biosoft (Cambridge, U.K.).

Cell Culture. Cells were grown either in MEM or IMDM supplemented with 10% FBS and maintained as monolayers in both culture flasks and roller bottles at 37°C under humidified 95% air:5% CO₂. Cells were harvested by exposure for 10 min to 0.002% EDTA in phosphate-buffered saline at pH 7.35. Harvested cells were washed, resuspended in HBSS, and counted using a hemocytometer. All cells used in these experiments were harvested during the log growth phase.

Binding Assays. Binding assays were conducted in a reaction buffer composed of HBSS containing 25 mM HEPES and 10 mM serine-borate. Serine-borate was added to block metabolism of LTC₄ (6). After completion of studies to optimize time, pH, and temperature, incubations were conducted in pH 7.35 reaction buffer at 4°C, in a shaking water bath for 30 min. Assay tubes contained 10⁵-10⁷ cells, 20-70 fmol [³H]-LTC₄ (specific activity 40 Ci/mmol) and reaction buffer in a total volume of 50-100 μ l. Nonspecific binding was assessed by determining the binding of [³H]-LTC₄ in the presence of excess unlabeled LTC₄ (16 μ M). All binding assays were conducted in triplicate or quadruplicate.

PROSTAGLANDINS

Binding assays were terminated by dilution with 3 ml of ice-cold HBSS. The cell-bound radioactivity was recovered either by centrifugation at 2000 x g for 5 min to pellet the cells followed by aspiration of the supernatant or by filtration through Whatman GF/B filters on a Yeda filtration manifold. Retentates were solubilized in scintillation fluid (Aquasol-2), and bound radioactivity was assessed on a Tracor Analytic Mark III scintillation counter. The centrifugation and filtration methods yielded similar recoveries of tritiated ligand. Scatchard analyses were performed by incubating aliquots of cells with tritiated ligand and graded levels of unlabeled ligand from 0 to 16 μ M/assay tube. The resulting displacement curves were transformed to Scatchard plots using LIGAND. All experiments reported herein were replicated at least once, and results are presented as means \pm SEM unless otherwise indicated. Kinetic data were evaluated using KINETIC.

Binding Specificity: Eicosanoids and Leukotriene Antagonists. Specificity of LTC₄ binding was assessed by adding 1 μ g of selected eicosanoids (100 μ l total volume) to assay tubes. The following eicosanoids were individually tested: LTC₄, LTA₄, LTB₄, LTD₄, LTE₄, PGA₂, PGB₂, PGD₂, PGE₂, PGF_{2 α} , 5-HETE, and 12-HETE. Additional binding assays were conducted in the presence of varying concentrations of the putative leukotriene receptor antagonists LY 171883, FPL 55712, or REV 5901-5 and using graded concentrations of the isomer 14,15-LTC₄.

Cationic and Nucleotide Requirements. Cells were harvested in Ca²⁺,Mg²⁺-free HBSS that contained 0.002% EDTA. The pelleted cells were washed twice in Ca²⁺,Mg²⁺-free HBSS and aliquoted into four groups for binding assays. Group (a) binding assays were conducted in 100 μ l of Ca²⁺,Mg²⁺-free HBSS containing 0.02% EDTA; group (b) contained Ca²⁺,Mg²⁺-free HBSS; group (c) contained complete HBSS (9.5 x 10⁻⁴ M Ca²⁺ and 9.0 x 10⁻⁴ M Mg²⁺); and group (d) contained M199. Nucleotide requirements were assessed by modifying the standard ligand assay to include 1 μ g/tube of cAMP, ATP, or GTP.

Examination of Other Eicosanoid Receptors on V79 Cells. Specific binding to V79 cells by PGD₂, PGE₂, PGF_{2 α} , LTD₄, LTE₄, and LTB₄ was examined by a modification of the standard LTC₄ ligand assay replacing the [³H]-LTC₄ with the other [³H]-labeled eicosanoids. Nonspecific binding was determined by adding a 100-fold molar excess of the respective unlabeled eicosanoid.

High-Performance Liquid Chromatography. Purity of leukotrienes was routinely monitored by high-performance liquid chromatography (HPLC) prior to use in binding assays. Reversed-phase HPLC was conducted as previously described (2,7) using either a Beckman or LKB GTi system with an Ultrasphere (Beckman Inc., Columbia, MD) C-18 column, 4.6 x 250 mm, packed with 5- μ m particles. Leukotrienes were eluted using 35% (v/v) acetonitrile/water containing 0.1% acetic acid at a pH adjusted to 5.8 with ammonium hydroxide and at a flow rate of 1.0 ml/min. Unlabeled leukotrienes were detected by absorbance at 280 nm. Tritiated leukotrienes were located on chromatographs by collecting fractions and assessing radioactivity with liquid scintillation counting or with an HPLC flow-through radiation monitor (RAMONA-D; IN/US, Inc.).

Metabolism of [³H]-LTC₄ was assessed by incubating 10⁶ cells with 112 fmol

PROSTAGLANDINS

[^3H]-LTC₄ at 4°C for periods of up to 1 hr. Following incubation, labeled material was extracted from the assay mixture containing cells and medium as described (2). Briefly, the pH of the medium was adjusted to 3.0 with HCl, followed by addition of 100 μl of isopropyl alcohol and 2.0 ml of ethyl acetate. This mixture was sonicated to maximize dissolution of the cellular membrane and centrifuged at 1000 \times g for 5 min. More than 98% of the radiolabel was extracted. The extract was evaporated to dryness, resuspended in HPLC mobile phase buffer, and analyzed by HPLC. Radioactivity in the eluate was identified by coelution with known standards.

Statistical Analyses. All experiments were replicated at least once, with equivalent results. Scatchard analyses were derived from displacement curves in duplicate. Other determinations were conducted in triplicate. Differences between treatments were assessed by student's t-test.

Results

Optimization of Binding Assay. The pH dependence of [^3H]-LTC₄ binding was examined using whole cells. Cells were pelleted by centrifugation, and then resuspended in medium in which the pH of the reaction buffer was adjusted with NaOH or HCl to 6.2, 6.8, 7.35, 8.0, 8.4, 8.8, or 9.2. Binding assays were conducted as described in Methods. Binding plateaued between pH 6.2 and 8.0 (Fig. 1) and decreased at higher pH values (>8.0). Subsequent binding assays were conducted at pH 7.35.




Fig. 1. Optimum pH for Binding of [^3H]-LTC₄ to V79 Cells. Total binding (■) was determined in assay tubes containing 10⁶ cells and 1.3 nM [^3H]-LTC₄, incubated in 50 μl assay buffer in which pH was adjusted with either NaOH or HCl. Nonspecific binding (□) was assessed in parallel tubes containing 16 μM unlabeled LTC₄. Mean \pm S.D.

PROSTAGLANDINS

Binding assays were optimized for incubation time and temperature. Parallel sets of tubes with or without $1\ \mu\text{M}$ unlabeled LTC_4 were incubated for 0, 15, 30, 45, or 60 min at 4° , 22° and 37°C . This experiment was conducted in the absence of serine-borate to assess the contribution of cellular levels of γ -glutamyl transpeptidase to binding. Radiolabeled LTC_4 was rapidly bound by cells (Fig. 2) and binding approached maximal levels within 15 min at either 4°C or 22°C . Binding at 37°C was lower and more variable than at lower temperatures (data not shown). HPLC analyses (reported in reference 2) confirmed catabolism of $[\text{^3H}]\text{-LTC}_4$ at the higher temperatures. Parallel groups of tubes were incubated in the absence of cells (cell blanks) at both 4°C and 22°C . Because binding at 4°C and 22°C in both the nonspecific and cell blank groups were similar, for clarity only the data from the 4°C incubation for these two groups are included in Fig. 2. A better estimate of nonspecific binding was obtained by increasing unlabeled LTC_4 from $1\ \mu\text{M}$ to $16\ \mu\text{M}$. This reduced nonspecifically bound radioactivity to levels not different from bound radioactivity in the absence of cells (data not shown). On the basis of these results, subsequent binding assays were conducted in triplicate at 4°C for 30 min, and nonspecific binding was assessed in the presence of $16\ \mu\text{M}$ LTC_4 .





Fig. 2. Time and Temperature Dependence of $[\text{^3H}]\text{-LTC}_4$ Binding to V79 Cells. Assay tubes containing 5×10^5 cells and $1.3\ \text{nM}$ $[\text{^3H}]\text{-LTC}_4$ in $50\ \mu\text{l}$ assay buffer were incubated for the indicated times at 4°C (●) or 24°C (■). Parallel series of tubes were incubated at 4°C containing $1\ \mu\text{M}$ unlabeled LTC_4 (□) or lacking cells (Δ). Mean \pm S.D.

Association and Dissociation of $[\text{^3H}]\text{-LTC}_4$. To determine the rate of association of $[\text{^3H}]\text{-LTC}_4$ with the receptor, aliquots of the cells were incubated for 2, 4, 6, 10, 20, 30, and 60 min (Fig. 3). To determine the dissociation rate, 10 min after the incubations were initiated, $16\ \mu\text{M}$ of unlabeled LTC_4 was added to a parallel set, and those incubations were terminated at the indicated times (Fig. 4). KINETIC was used to generate lines that best fit the data.

PROSTAGLANDINS



Association (Fig. 3) and Dissociation (Fig. 4) of $[^3\text{H}]\text{-LTC}_4$ by Intact V79 Cells. 10^6 cells/tube were incubated at 4°C with 1.3 nM $[^3\text{H}]\text{-LTC}_4$ in $50 \mu\text{l}$ assay buffer. Dissociation rate was monitored in tubes to which $10 \mu\text{l}$ unlabeled LTC_4 ($16 \mu\text{M}$ final concentration) was added after an initial incubation of 10 min. All incubations were terminated by filtration at indicated times. Curves were generated using KINETIC and a two-site model (Association: 54% $K_{\text{ass}1} = 0.032 \pm 0.028$; 46% $K_{\text{ass}2} = 0.86 \pm 0.23$. Dissociation: 41% $K_{\text{dss}1} = 0.032 \pm 0.013$; 59% $K_{\text{dss}2} = 0.77 \pm 1.25$).

Identification of Binding Products. V79 cells metabolize LTC_4 to LTD_4 and LTE_4 when incubations are conducted at 37°C (2). Therefore, reversed phase HPLC was used to assess radiolabeled products obtained after incubation of V79 cells with $[^3\text{H}]\text{-LTC}_4$. No metabolism of LTC_4 was detected during incubations at 4°C for up to 1 hr (Fig. 5), demonstrating that binding was attributable to LTC_4 and not a metabolic product such as LTD_4 or LTE_4 . This also suggested that the binding process did not alter the ligand, and that when released from the binding site LTC_4 could bind again.




Fig. 5. High Performance Liquid Chromatography (HPLC) Analysis of $[^3\text{H}]\text{-LTC}_4$ Binding Products. V79 cells were incubated with $[^3\text{H}]\text{-LTC}_4$, then extracts were analyzed by HPLC as described in Methods. Units of radioactivity are not provided on the abscissa, because area under the LTC_4 peak (10,000 dpm) accounts for all labeled material recovered. Arrows indicate regions of elution of authentic standards of LTD_4 and LTE_4 .

Binding Specificity. V79 cells were incubated with selected tritiated eicosanoids to determine the presence of other classes of eicosanoid receptors or specific binding sites. Incubations with tritiated PGD_2 , PGE_2 , and $\text{PGF}_{2\alpha}$ did not result in tracer binding that was displaceable by 100-fold molar excess of the respective unlabeled ligand. Incubations

PROSTAGLANDINS

with tritiated LTD₄ resulted in minimal and inconsistent levels of specific binding (data not shown). Glutathione at concentrations of up to 3 μ M had no effect on [³H]-LTC₄ binding (data not shown).

Table 1. Specificity of [³H]-LTC₄ Binding.^a

Eicosanoid	Control Binding (%) ^b
LTC ₄	16.6 ± 1.9 ^c
LTA ₄	98.4 ± 5.2
LTB ₄	105.4 ± 8.5
LTD ₄	107.3 ± 15.9
LTE ₄	94.5 ± 8.7
PGA ₂	79.8 ± 8.5 ^c
PGB ₂	107.5 ± 5.1
PGD ₂	95.6 ± 3.7
PGE ₂	106.9 ± 3.5
PGF _{2α}	126.3 ± 11.9
5-HETE	100.1 ± 4.8
12-HETE	116.3 ± 13.6

^a 10⁶ cells/tube in 50 μ l buffer were incubated at 4°C for 30 min with 30 fmol [³H]-LTC₄ and 1 μ g of each eicosanoid.

^b (\bar{x} ± SEM)

^c P < .001 by t-test

Table 1 shows the capacity of various eicosanoids to displace [³H]-LTC₄. Only LTC₄ and PGA₂ competed with [³H]-LTC₄ for binding to V79 cells. The isomer of LTC₄, 14,15-LTC₄, competed with [³H]-LTC₄ for binding, although the displacement curve for 14,15-LTC₄ was displaced appreciably to the right of that by LTC₄ (Fig. 6).

To assess further the specificity of LTC₄ binding, V79 cells were incubated with compounds that have reported leukotriene antagonist activity. The compounds LY 171883, FPL 55712, or REV 5901-5 did not affect LTC₄ binding (Fig. 7). Interestingly, binding actually tended to be higher in the presence of LY171883 or REV5901-5.




Fig. 6. Competition by 14,15-LTC₄ for Binding to V79 Cells. Parallel displacement curves were conducted using LTC₄ (●) or the 14,15 isomer of LTC₄ (Δ).

PROSTAGLANDINS




Fig. 7. Effect of Leukotriene Antagonists on LTC₄ Binding. 10⁶ V79 cells were incubated at 4°C for 30 min with 1 nM [³H]-LTC₄ and differing concentrations of either LTC₄ (●), LY 171883 (□), FPL 55712 (■), or REV 5901-5 (Δ).

LTC₄ and LTD₄ binding to tissues may be influenced by monovalent and divalent cations (8,9,10), and nucleotides (10,11). To determine if media components influence the binding of LTC₄, V79 cells were incubated with [³H]-LTC₄ in media of differing compositions. No difference in binding was detected when assays were conducted in M199, HBSS, Ca²⁺/Mg²⁺-free HBSS, Ca²⁺/Mg²⁺-free HBSS containing 0.01% EDTA, or 25 mM Tris-1 mM CaCl₂ (pH 7.35 in all buffers). Also, binding of [³H]-LTC₄ was not significantly altered by inclusion of 1 μg/100 μl of cAMP, ATP, or GTP in HBSS (data not shown).

Scatchard Analyses. Scatchard analyses were conducted using either live cells or cells that were previously frozen and stored in pellets at -80°C. To determine if freezing affected Scatchard analyses, pools of V79 cells were divided into two aliquots. One aliquot was placed on ice for 12 hr, while the other was pelleted, frozen, and stored for 12 hr at -80°C. Subsequent Scatchard analyses revealed no differences in LTC₄ binding abundance or affinities (data not shown). A summary of Scatchard analyses conducted on eight separate pools of cells was curvilinear, having high-affinity [Kd = 2.5 ± 0.63 nM; 9.9 × 10⁵ sites/cell] and low-affinity [Kd = 350 ± 211 nM; 2.7 × 10⁶ sites/cell] binding sites (Fig. 8).

Discussion

LTC₄ plays a role in controlling the lungs (12,13,14,15), cardiovascular system (12,16) and smooth muscle (12). LTC₄-immunoreactive neurons identified in the hypothalamic median eminence (17), in which LTC₄ has been demonstrated as a potent mediator of gonadotropin-releasing hormone (18) and LTC₄ in very small amounts induces gonadotropin release from anterior pituitary cells *in vitro* (17). Binding of LTC₄ to rat lung fibroblasts was

PROSTAGLANDINS

correlated with stimulation of collagen by the treated cells (19). However, the contribution of LTC_4 in regulation of some physiologic processes has proven controversial because a number of cell and tissue types contain "binding sites" for LTC_4 without demonstrable biologic responsiveness to LTC_4 (20).




Fig. 8. Scatchard Analysis of $[\text{H}]\text{-LTC}_4$ Binding Sites on V79 Cells. Incubations were conducted at 4°C for 30 min using 10^6 cells and 1.3 nM of $[\text{H}]\text{-LTC}_4$ per tube, while concentrations of unlabeled LTC_4 ranged from 0-16 μM . Displacement curves were transformed to Scatchard plots using LIGAND, which revealed high-affinity ($K_d = 2.5 \pm 0.63$ nM) and low-affinity ($K_d = 350 \pm 211$ nM) binding sites.

A series of criteria has been established for distinguishing receptor-mediated events from events of a less specific nature. One summarization of the events that classically elevate the events of a tissue-ligand interaction to a receptor-mediated event (21) included the criteria of drug displacement, correlation between drug affinity *in vitro* and pharmacological potency, regional distribution, subcellular distribution, stereospecificity, saturability, reversibility and high affinity. Our studies indicate that the interaction of LTC_4 with V79 cells satisfies most, but not all, of the criteria describing a classical "receptor": our studies demonstrate reasonable levels of saturability, reversibility, stereospecificity, pharmacologic potency, and high affinity. Regional distribution of binding is not applicable in our studies using a cell line. The issue of subcellular distribution is assessed in the companion communication (5), and the issue of drug displacement is addressed below.

As outlined in Table 1, competition with $[\text{H}]\text{-LTC}_4$ for binding to the intact V79 cell was specific for LTC_4 and was not displaceable to a significant degree by other classes of leukotrienes or by a molecular component of LTC_4 , glutathione. The 14,15-isomer of LTC_4 exhibited approximately 10% potency. LTC_4 binding was not displaceable by a number of structurally similar and pharmacologically similar compounds, including

PROSTAGLANDINS

a long list of prostaglandins (Table 1). The inhibition of binding by PGA_2 was unusual but repeatable and it is not known whether this was a direct or indirect effect on the receptor protein. Specific antagonists for LTC_4 are not presently available. There are several antagonists for LTD_4 and LTE_4 , including FPL 77512 (9,22), LY 171883 (23), and REV 5901-5 (24), but these compounds do not antagonize LTC_4 effects or binding to a great degree (9,22,24). Therefore, it was not surprising that they were ineffective antagonists to LTC_4 binding by the V79 cell, but they indicate common specificity patterns among LTC_4 receptors. The specificity of the receptor was further confirmed when these LTD_4 and LTE_4 antagonists did not compete for the LTC_4 binding sites.

The curvilinear Scatchard plots describing LTC_4 binding to intact V79 cells suggested either multiple classes of binding sites or negative cooperativity in LTC_4 binding. Because the curvilinear Scatchard plots were not demonstrable in binding assays using plasma membrane or nuclear V79 cell preparations (5), it seems most likely that multiple classes of binding sites were revealed in binding assays using intact V79 cells. While the low-affinity binding sites on V79 cells were more abundant than the high-affinity sites (low-affinity binding was approximately 70% of total specific binding), the high-affinity sites on V79 cells were relatively abundant in comparison with reported abundance in other cell lines. For example, the cumulative binding site abundance using intact V79 cells was approximately tenfold higher than that reported for the DDT1M2F hamster smooth muscle cell line (25).

The binding affinities of LTC_4 to V79 cells correlated with doses of LTC_4 that decreased the radiosensitivity of this cell line. In radioprotection studies, pretreatment with 0.5×10^{-6} M LTC_4 was minimally effective, while 2.5×10^{-6} M LTC_4 conferred greater radioprotection (2). Thus LTC_4 -conferred radioprotection in the V79 cell line, while not a usual physiologic event, nevertheless provides a correlation of pharmacological potency with the affinity range determined for LTC_4 binding.

V79 cells metabolize LTC_4 to LTD_4 and LTE_4 when cultured at 37°C , and both cells and tissue culture medium possess γ -glutamyl transpeptidase activity (2). Enhanced degradation of LTC_4 may explain the decrease in binding observed with increasing incubation temperature (Fig. 2). The addition of serine-borate, a transition state inhibitor of γ -glutamyl transpeptidase (6), decreased the possibility of LTC_4 degradation in later experiments. HPLC analysis of products from the binding assay suggested that LTC_4 was not decomposed or metabolized during binding studies conducted at 4°C .

The LTC_4 binding site in V79 cells, like the rat glomeruli binding site (26), did not appear to require Na^+ , Ca^{2+} , or Mg^{2+} for binding activity. Guanine nucleotides were reported to regulate the binding of LTD_4 to guinea pig lung membranes (10), but appeared to have no effect on LTC_4 receptors in either the guinea pig myocardium (8) or in V79 cells. The V79 cell was reportedly responsive to agents that stimulate cyclic AMP, including prostaglandins (27). The latter is interesting in light of our inability to demonstrate specific binding of several tritiated prostaglandins by this cell line. In particular, we did not observe specific binding of PGE_2 by V79 cells. It was reported in a prior study that pretreatment with PGE_2 did not confer radioprotection of V79 cells (28), which is not

PROSTAGLANDINS

inconsistent with the hypothesis that eicosanoid-induced radioprotection is receptor mediated.

The mechanism by which LTC_4 confers radioprotection to the V79 cell is unknown, although leukotrienes may induce synthesis of cAMP (29), cGMP (29), or other eicosanoids (30), which may in turn have protective effects. Further studies are needed to clarify the mechanism by which LTC_4 protects V79 cells from the deleterious effects of irradiation, although our studies suggest that LTC_4 may interact with V79 cells through a receptor-mediated event. In view of its abundant LTC_4 binding capacity, the V79 cell line may provide both an excellent source for leukotriene receptor purification and a model for defining certain cellular responses to leukotrienes.

Acknowledgements

The authors gratefully acknowledge gifts of V79 cells from Dr. E. V. Holahan, leukotrienes from Dr. J. Rokach, prostaglandins from Dr. D. Morton, and leukotriene antagonists from Dr. A. Taub, Mr. W. Fields and Dr. T. P. Pruss. Valuable technical assistance was provided by C. Hollies. J. Koeser and M. Waldbillig provided skilled secretarial assistance. This work was supported by NIH HD20780, USUHS Protocol C08517, and Defense Nuclear Agency Work Unit #B2152. The views presented in this paper are those of the authors. No endorsement by the Defense Nuclear Agency or the Department of Defense has been given or should be inferred.

References

1. Furuta Y., E.R. Hall, S. Sanduja, T. Barkley Jr., and L. Miles. Prostaglandin Production by Murine Tumors as a Predictor for Therapeutic Response to Indomethacin. *Cancer Res.* **48**:3002. 1988.
2. Walden, T.L., E.V. Holahan, and G.N. Catravas. Development of a Model System to Study Leukotriene-Induced Modification of Radiation Sensitivity in Mammalian Cells. *Prog. Lipid Res.* **25**:587. 1986.
3. Walden Jr, T.L., M.L. Patchen, and T.J. MacVittie. Leukotriene-Induced Radioprotection of Hematopoietic Stem Cells in Mice. *Radiat. Res.* **113**:388. 1988.
4. Walden Jr, T.L. Pretreatment with Leukotriene C_4 Enhances the Whole-Animal Survival of Mice Exposed to Ionizing Radiation. *Ann. N.Y. Acad. Sci.* **524**:431. 1988.
5. Liu, Y.X., D.S. Watt, T.L. Walden Jr, and T.A. Fitz. Interaction of Leukotriene C_4 and Chinese Hamster Lung Fibroblasts (V79A03 Cells). 2. Subcellular Distribution of Binding and Unlikely Role of Glutathione-S-Transferase. *Prostaglandins*, this volume.
6. Tate, S.S., and A. Meister. Serine-Borate Complex as a Transition State Inhibitor of Gamma-Glutamyl Transpeptidase. *Proc. Natl. Acad. Sci. USA* **75**:4806. 1978.
7. Borgeat, P., and B. Samuelsson. Arachidonic Acid Metabolism in Polymorphonuclear Leukocytes: Effects of Ionophore A23187. *Proc. Natl. Acad. Sci. USA* **76**:2148. 1979.
8. Hogaboam, G.K., S. Mong, J.M. Stadel, and S.T. Crooke. Characterization of Guinea Pig Myocardial Leukotriene C_4 Binding Sites: Regulation by Cations and Sulfhydryl-Directed Reagents. *Mol. Pharmacol.* **27**:236. 1985.

PROSTAGLANDINS

9. Rovati, G.E., D. Oliva, L. Sautebin, G.C. Folco, A.F. Welton, and S. Nicosia. Identification of Specific Binding Sites for Leukotriene C₄ in Membranes from Human Lung. *Biochem. Pharmacol.* **34**:2831. 1985.
10. Mong, S., H.-L. Wu, G.K. Hogaboom, M.A. Clark, J.M. Stadel, and S.T. Crooke. Regulation of Ligand Binding to Leukotriene D₄ Receptors: Effects of Cations and Guanine Nucleotides. *Eur. J. Pharmacol.* **106**:241. 1984.
11. Hogaboom, G.K., S. Mong, H.-L. Wu, and S.T. Crooke. Peptidoleukotrienes: Distinct Receptors for Leukotriene C₄ and D₄ in the Guinea Pig Lung. *Biochem. Biophys. Res. Commun.* **116**:1136. 1983.
12. Sirois, P. Pharmacology of the Leukotrienes. *Adv. Lipid Res.* **21**:79. 1985.
13. Samhoun, N.M., and P.J. Piper. In: *Leukotrienes and Other Lipooxygenase Products*. (P.J. Piper, ed.) Research Studies Press, New York, 1982, p. 161.
14. Dahlen, S.-E. Pulmonary Effects of Leukotrienes. *Acta Physiol. Scand. Suppl.* **512**:1. 1983.
15. Dahlen, S.-E., G. Hansson, P. Hedqvist, T. Bjorck, E. Granstrom, and B. Dahlen. Allergen Challenge of Lung Tissue from Asthmatics Elicits Bronchial Contraction That Correlates With the Release of Leukotrienes C₄, D₄, and E₄. *Proc. Natl. Acad. Sci. USA* **80**:1712. 1983.
16. Feuerstein, G., Z. Zukowska-Grojec, and I.J. Kopin. Cardiovascular Effects of Leukotriene D₄ in SHR and WKY Rats. *Eur. J. Pharmacol.* **76**:107. 1981.
17. Hulting, A.L., J.A. Lindgren, T. Hokfelt, P. Eneroth, S. Werner, C. Patrono, and B. Samuelsson. Leukotriene C₄ as a Mediator of Luteinizing Hormone Release From Rat Anterior Pituitary Cells. *Proc. Natl. Acad. Sci. USA* **82**:3834. 1985.
18. Wisner-Provost, A., K. Gerozissis, M.C. Bommelaer, C.A. Renard, C. Rougeot, F.A. Levi, and F. Dray. Eicosanoids in Relation With LHRH Secretion. *Adv. Prostaglandin Thromboxane Leukotriene Res.* **16**:235. 1986.
19. Phan S.H., B.M. McGarry, K.M. Loeffler, and S.L. Kunkel. Binding of Leukotriene C₄ to Rat Lung Fibroblasts and Stimulation of Collagen Synthesis *In Vitro*. *Biochemistry* **27**:2846. 1988.
20. Sun, F.F., L.Y. Chau, and K.F. Austen. Binding of Leukotriene C₄ by Glutathione Transferase: A Reassessment of Biochemical and Functional Criteria for Leukotriene Receptors. *Federation Proceedings* **46**:204. 1987.
21. Laduron, P.M. Criteria for Receptor Sites in Binding Studies. *Biochem. Pharmacol.* **33**:833. 1984.
22. Drazen, J.M., K.F. Austen, R.A. Lewis, D.A. Clark, G. Goto, A. Marfat, and E.J. Corey. Comparative Airway and Vascular Activities of Leukotrienes C₄ and D₄ *In Vivo* and *In Vitro*. *Proc. Natl. Acad. Sci. USA* **77**:4351. 1980.
23. Fleisch, J.H., L.E. Rinkema, and W.S. Marshall. Commentary: Pharmacological Receptors for the Leukotrienes. *Biochem. Pharmacol.* **33**:3919. 1984.
24. Gordon, R.J., J. Travis, H.R. Godfrey, D. Sweeny, P.S. Wolf, T.P. Pruss, E. Neiss, J. Musser, U. Chakraborty, H. Jones, and M. Leibowitz. *In Vivo* Activity of a Lipooxygenase Inhibitor and Leukotriene Antagonist. Abstract #261 in *Prostaglandins and Leukotrienes '84*, Washington, D.C. 1984.
25. Clark, M.A., M. Cook, S. Mong, G.K. Hogaboom, R. Shorr, J. Stadel, and S.T. Crooke. Leukotriene C₄ ([³H]LTC₄) Binding to Membranes Isolated From a Hamster Smooth Muscle Cell Line (DDT1MF2). *Life Sci.* **35**:441. 1984.

PROSTAGLANDINS

26. Ballerman, B.J., R.A. Lewis, E.J. Corey, K.F. Austin, and B.M. Brenner. Identification and Characterization of Leukotriene C₄ Receptors in Isolated Rat Renal Glomeruli. *Circ. Res.* 56:324. 1985.
27. Lehnert, S. Modification of Postirradiation Survival of Mammalian Cells by Intracellular Cyclic AMP. *Radiat. Res.* 62:107. 1975.
28. Holahan, E.V., W.F. Blakely, and T.L. Walden. In: *Prostaglandin and Lipid Metabolism in Radiation Injury* (T.L. Walden and H.N. Hughes, eds.) Plenum Press, New York, 1982, p. 253.
29. Vesin, M.F., S. Bourgoin, D. Leiber, and S. Harbon. Lipxygenase and Cyclooxygenase Products of Arachidonic Acid in Uterus. Selective Interaction With cGMP and cAMP Systems. *Prost. Leuko. Med.* 13:75. 1984.
30. Feuerstein, N., M. Foegh, and P.W. Ramwell. Leukotrienes C₄ and D₄ Induce Prostaglandin and Thromboxane Release From Rat Peritoneal Macrophages. *Br. J. Pharmacol.* 72:389. 1981.

Editor: P. Ramwell

Received: 5-18-87

Accepted 8-16-90